Selecta Biosciences Inc. (RNAC): Price-to-Revenue Ratio

Cartesian Therapeutics (RNAC) maintains high scientific authority due to its safe RNA therapy methods. The price-to-sales ratio visualizes market expectations, where 189.00 captures the current value of the indicator. Technological superiority enables the company to collaborate profitably with pharmaceutical behemoths. Despite a narrow specialization in oncology and autoimmune pathologies, risks are mitigated by external grants and multi-stage research.

RNAC: Cartesian Therapeutics P/S Multiple 02/21/2024 - 11/13/2026

Metric breakdowns and analytics for Cartesian Therapeutics Inc (RNAC)

- current price and projected stock value:

Price Chart selectabio.com|RNAC - Price Target Chart

- stock exchange capitalization data:

Market Value Cartesian Therapeutics Inc|RNAC - Real Price to Acquire Entire Company

- issuer book value statistics:

Accounting Value of a Share Cartesian Therapeutics|RNAC - Book Capitalization|Market Value to Equity Ratio selectabio.com|RNAC - Company Total Assets

- business debt structure and liquidity details:

Debt to Capital Cartesian Therapeutics|RNAC - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Selecta Biosciences Inc.|RNAC - Company Aggregate Debts|Debts to Book Value Cartesian Therapeutics Inc|RNAC - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Cartesian Therapeutics|Intermediate Liquidity Ratio selectabio.com

- earnings and valuation multiples information:

RNAC - Net Profit|Expected Net Income Cartesian Therapeutics|RNAC - P/E Multiple|Projected Price to Earnings Ratio Selecta Biosciences|RNAC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cartesian Therapeutics Inc|RNAC - Operating profit EBITDA|Net earnings per share (EPS TTM) Cartesian Therapeutics|RNAC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months selectabio.com|RNAC - Net earnings per share growth this year|Expected net earnings per share growth next year Cartesian Therapeutics

- issuer revenue and sales details:

RNAC - Revenue and Sales Volume|Company Future Sales Volume selectabio.com|RNAC - P/S Multiple|Forward P/S Multiple Cartesian Therapeutics Inc

General company analysis:RNAC - selectabio.com

When constructing a long-term portfolio, fundamental screening requires aligning a business's market value with its ability to generate revenue. The price-to-sales ratio measures the investor's premium paid per unit of revenue, which is critical for Cartesian Therapeutics (RNAC), as its cell therapy development model is not yet profitable, reflecting a dependence on venture capital infusions within the P/S multiple trend.

Who Cartesian Therapeutics competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CLLS (Cellectis S.A.)|CRBU: P/S Multiple|Price-to-Revenue Multiple instilbio.com TIL|GNTA (Genenta Science SpA) - P/S Multiple|Price to Sales Century Therapeutics Inc IPSC|Price-to-Revenue Ratio Jasper Therapeutics (JSPR)|sentibio.com - Market Cap to Revenue Ratio|P/S Multiple ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio